Last update 15 Sep 2024

Aganepag isopropyl

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Aganepag, Aganepag isopropyl (USAN), AGN-210961
Target
EP2
Mechanism
EP2 agonists(Prostanoid EP2 receptor agonists)
Therapeutic Areas
Eye Diseases
Active Indication-
Inactive Indication
GlaucomaGlaucoma, Open-Angle
Originator Organization
Allergan Ltd. (Ireland)
Active Organization-
Inactive Organization
Allergan Ltd. (Ireland)
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-

Structure

Molecular FormulaC27H37NO4S
InChIKeyGKRBCKDGBDUAIQ-URXFXBBRSA-N
CAS Registry910562-20-8

Related

1
Clinical Trials associated with Aganepag isopropyl
NCT01110499 / CompletedPhase 2
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
100 Clinical Results associated with Aganepag isopropyl
Login to view more data
100 Translational Medicine associated with Aganepag isopropyl
Login to view more data
100 Patents (Medical) associated with Aganepag isopropyl
Login to view more data
1
Literatures (Medical) associated with Aganepag isopropyl
01 Apr 2019British journal of pharmacologyQ2 · MEDICINE
Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Q2 · MEDICINE
100 Deals associated with Aganepag isopropyl
Login to view more data

External Link

KEGGWikiATCDrug Bank
D09863--
DB16085

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glaucoma, Open-AnglePhase 2
US
Allergan Ltd. (Ireland)
01 Jun 2010
GlaucomaPhase 2-
Allergan Ltd. (Ireland)
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01110499 (CTgov)
Phase 2
Glaucoma, Open-Angle
163
(Part 1, AGN-210961 Formulation 1)
pcukwyduzj(oarfzyvpoa) = mrnlhxqywo hdgfelwbjr (desdsukiic, oxqcfvsuwo - omqvzyoixc)
View more
-
05 Aug 2014
(Part 1, AGN-210961 Formulation 2)
pcukwyduzj(oarfzyvpoa) = lsqtlciydc hdgfelwbjr (desdsukiic, jwxhvllxdr - bzmhalnkui)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free